Критерии продолжительности иммобилизации пораженной конечности при диабетической нейроостеоартропатии Шарко

Длительная разгрузка является основным методом лечения острой стадии артропатии Шарко. Предполагается, что показания к прекращению иммобилизации и переходу к ходьбе должны быть основаны на клинических признаках прекращения воспаления и данных объективных методов. Однако в современной литературе отсутствует единое мнение о том, какие обследования и методы достаточны для определения завершения острой стадии и перевода больного от иммобилизации к ходьбе. В работе обсуждаются клинические методы оценки активности артропатии и специальные исследования, применяемые для этой цели, их достоинства и недостатки.

диабетическая нейроостеоартропатия, стопа Шарко, термометрия, магнитно-резонансная томография

1. Rogers LC, Frykberg RG, Armstrong DG, Boulton AJM, Edmonds M, Van GH, et al. The Charcot Foot in Diabetes. Diabetes Care 2001;34(9):2123-2129. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc11-0844 doi: 10.2337/dc11-0844.

2. Sinha S, Munichoodappa CS, Kozak GP. NEURO-ARTHROPATHY (CHARCOT JOINTS) IN DIABETES MELLITUS. Medicine 1972;51(3):191-210. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005792-197205000-00006 doi: 10.1097/00005792-197205000-00006.

3. Cofield RH, Morrison MJ, Beabout JW. Diabetic Neuroarthropathy in the Foot: Patient Characteristics and Patterns of Radiographic Change. Foot & Ankle International 1983;4(1):15-22. Available from: http://fai.sagepub.com/lookup/doi/10.1177/107110078300400104 doi: 10.1177/107110078300400104.

4. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJM. Diabetic Foot Syndrome: Evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003;26(5):1435-1438. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.26.5.1435 PubMed PMID: 12716801. doi: 10.2337/diacare.26.5.1435.

5. Chantelau EA, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging--a review of 71 cases. Swiss Med Wkly 2013;143. Available from: http://www.smw.ch/dfe/set_archiv.asp?target=10.4414/smw.2013.13831 PubMed PMID: 23897135. doi: 10.4414/smw.2013.13831.

6. Sandrow RE, Torg JS, Lapayowker MS, Resnick EJ. The Use of Thermography in the Early Diagnosis of Neuropathic Arthropathy in the Feet of Diabetics. Clinical Orthopaedics and Related Research 1972;88:31-33. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003086-197210000-00004 doi: 10.1097/00003086-197210000-00004.

7. Armstrong DG, Lavery LA. Monitoring healing of acute Charcot's arthropathy with infrared dermal thermometry. J Rehabil Res Dev 1997;34(3):317-321. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=9239625 PubMed PMID: 9239625.

8. Armstrong D, Lavery L, Liswood P, Todd W, Tredwell J. Infrared Dermal Thermometry for the High-Risk Diabetic Foot. Phys Ther 1997;77:169-175.

9. Armstrong D, Lavery L. Acute Charcot's Arthropathy of the Foot and Ankle. Phys Ther 1998;78:74-80.

10. Котухова ЯВ. Комплексная клинико-лучевая диагностика и медико-социальная реабилитация при диабетической остеоартропатии. Автореф. дис. к.м.н. Обнинск; 2002.

11. McCrory J, Morag E, Norkitis A, Barr M, Moser R, Caputo G, et al. Ulbrecht J Healing of Charcot fractures: skin temperature and radiographic correlates. The Foot 1998;8:158-165.

12. Moura-Neto A, Fernandes T, Zantut-Wittmann D, Trevisan R, Sakaki M, Santos A, et al. Charcot foot: skin temperature as a good clinical parameter for predicting disease outcome. Diabetes Res Clin Pract 2012;96:11-14.

13. Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001;44(11):2032-2037. Available from: http://link.springer.com/10.1007/s001250100008 PubMed PMID: 11719835. doi: 10.1007/s001250100008.

14. Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM, Manto A, et al. Six-Month Treatment With Alendronate in Acute Charcot Neuroarthropathy: A randomized controlled trial. Diabetes Care 2005;28(5):1214-1215. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.28.5.1214 PubMed PMID: 15855594. doi: 10.2337/diacare.28.5.1214.

15. Ruotolo V, Di Pietro B, Giurato L, Masala S, Meloni M, Schillaci O, et al. A New Natural History of Charcot Foot. Clinical Nuclear Medicine 2013;38(7):506-509. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201307000-00003 doi: 10.1097/RLU.0b013e318292eecb.

16. Eichenholtz S. Charcot Joints. With a foreword by Philip D Wilson. Springfield Illinois: Charles C. Thomas Publisher; 1966.

17. Classen JN, Rolley RT, Carneiro R, Martire JR. Management of foot conditions of the diabetic patient. Am Surg 1976;42(2):81-88. Available from: http://www.nlm.nih.gov/medlineplus/diabetescomplications.html PubMed PMID: 1247258.

18. Schlossbauer T, Mioc T, Sommerey S, Kessler SB, Reiser MF, Pfeifer K. Magnetic resonance imaging in early stage charcot arthropathy: correlation of imaging findings and clinical symptoms. Eur J Med Res 2008;13(9):409-414. Available from: http://www.nlm.nih.gov/medlineplus/diabetescomplications.html PubMed PMID: 18948232.

19. Edmonds M, Petrova N, Edmonds A, Elias D. What happens to the initial bone marrow oe-dema in the natural history of Charcot osteoarthropathy? Abstracts of the VIth Meeting of the Diabetic Foot Study Group of the EASD (Elsinore, Denmark, 10-13 Sept. 2006):24.

20. Zampa V, Bargellini I, Rizzo L, Turini F, Ortori S, Piaggesi A, et al. Role of Dynamic MRI in the follow-up of acute Charcot foot in patients with diabetes mellitus. Skeletal Radiol 2011;40(8):991-999. Available from: http://link.springer.com/10.1007/s00256-010-1092-0 doi: 10.1007/s00256-010-1092-0.

21. Thorning C, Gedroyc WMW, Tyler PA, Dick EA, Hui E, Valabhji J. Midfoot and Hindfoot Bone Marrow Edema Identified By Magnetic Resonance Imaging in Feet of Subjects With Diabetes and Neuropathic Ulceration Is Common but of Unknown Clinical Significance. Diabetes Care 2010;33(7):1602-1603. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc10-0037 PubMed PMID: 20413517. doi: 10.2337/dc10-0037.

22. Chantelau EA, Grützner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot?. Swiss Med Wkly 2014;144:144-13948. Available from: http://www.smw.ch/dfe/set_archiv.asp?target=10.4414/smw.2014.13948 PubMed PMID: 24764120. doi: 10.4414/smw.2014.13948.

23. Capriotti G, Chianelli M, Signore A. Nuclear medicine imaging of diabetic foot infection: results of meta-analysis. Nuclear Medicine Communications 2006;27(10):757-764. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006231-200610000-00002 doi: 10.1097/01.mnm.0000230065.85705.b3.

24. Papanas N, Zissimopoulos A, Maltezos E. The role of nuclear medicine in the diagnosis of common and specific diabetic infections. Hell J Nucl Med 2010;13(2):150-157. Available from: http://www.nlm.nih.gov/medlineplus/diabetescomplications.html PubMed PMID: 20808989.

25. Larcos G, Brown ML, Sutton RT. Diagnosis of osteomyelitis of the foot in diabetic patients: value of 111In-leukocyte scintigraphy. American Journal of Roentgenology 1991;157(3):527-531. Available from: http://www.ajronline.org/doi/abs/10.2214/ajr.157.3.1872240 doi: 10.2214/ajr.157.3.1872240.

26. Familiari D, Glaudemans AWJM, Vitale V, Prosperi D, Bagni O, Lenza A, et al. Can Sequential 18F-FDG PET/CT Replace WBC Imaging in the Diabetic Foot. Journal of Nuclear Medicine 2001;52(7):1012-1019. Available from: http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.110.082222 doi: 10.2967/jnumed.110.082222.

27. Bem R, Jirkovska A, Dubsky M, Fejfarova V, Buncova M, Skibova J, et al. Role of Quantitative Bone Scanning in the Assessment of Bone Turnover in Patients With Charcot Foot. Diabetes Care 2010;33(2):348-349. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc09-0950 doi: 10.2337/dc09-0950.

28. Pickwell KM, van Kroonenburgh MJ, Weijers RE, van Hirtum PV, Huijberts MS, Schaper NC. F-18 FDG PET/CT Scanning in Charcot Disease. Clinical Nuclear Medicine 2011;36(1):8-10. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201101000-00002 PubMed PMID: 21157199. doi: 10.1097/RLU.0b013e3181feeb30.

29. McGill M, Molyneaux L, Bolton T, Ioannou K, Uren R, Yue DK. Response of Charcot's arthropathy to contact casting: assessment by quantitative techniques. Diabetologia 2000;43(4):481-484. Available from: http://link.springer.com/10.1007/s001250051332 doi: 10.1007/s001250051332.

30. Mabilleau G, Petrova N, Edmonds ME, Sabokbar A. Number of circulating CD14-positive cells and the serum levels of TNF-α are raised in acute charcot foot. Diabetes Care;34(3):33. doi: 10.2337/dc10-1695.

31. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008;51(6):1035-1040. Available from: http://link.springer.com/10.1007/s00125-008-0992-1 PubMed PMID: 18389210. doi: 10.1007/s00125-008-0992-1.

32. Uccioli L, Sinistro A, Almerighi C, Ciaprini C, Cavazza A, Giurato L, et al. Proinflammatory Modulation of the Surface and Cytokine Phenotype of Monocytes in Patients With Acute Charcot Foot. Diabetes Care 2010;33(2):350-355. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc09-1141 PubMed PMID: 19880584. doi: 10.2337/dc09-1141.